Quantcast

Latest Macular edema Stories

2011-06-05 18:01:00

MARLOW, England, June 6, 2011 /PRNewswire/ -- Allergan announces today that the National Institute for Health and Clinical Excellence (NICE) has recommended OZURDEX(R) (dexamethasone 0.7mg intravitreal implant in applicator) for the treatment of macular oedema due to central retinal vein occlusion (CRVO) and also for branch retinal vein occlusion (BRVO) where laser photocoagulation is neither beneficial nor appropriate. RVO is an eye condition that can lead to severe damage to the...

2011-04-13 05:30:00

RICHMOND, Va., April 13, 2011 /PRNewswire/ -- Richmond surgeon, Dr. Stewart O'Keefe, was recently elected as president of the Central Virginia Juvenile Diabetes Research Foundation's Board of Directors. As a Retina Surgeon at Retina Institute of Virginia (RIV) and Stony Point Surgery Center, Dr. O'Keefe performs over 500 surgeries each year, many for complications of diabetes such as diabetic macular edema. The Juvenile Diabetes Research Foundation (JDRF) has over 100 chapters worldwide,...

2010-12-20 00:10:00

TARRYTOWN, N.Y., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, December 20, to discuss results of the Phase 3 COPERNICUS study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) and the week 52 follow-up results of the Phase 2 DA VINCI study in patients with diabetic macular edema (DME). A press release will be issued prior to the call....

2010-09-01 00:29:00

LEUVEN, Belgium, September 1, 2010 /PRNewswire-FirstCall/ -- - Data Presented at ASRS Confirm Previous Phase III Findings and Microplasmin's Potential to Transform the Treatment of Retinal Disorders ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of...

2010-07-21 22:46:00

GREENWOOD VILLAGE, Colo., July 21 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE) today announced the initiation of a Phase II clinical trial of Optina(TM) for the treatment of diabetic macular edema, an early stage of diabetic retinopathy. Diabetic macular edema is responsible for most vision loss in patients with diabetes mellitus. Ampio Pharmaceuticals has completed a formal agreement with St Michael's Hospital, Toronto, Canada as a final step for...

2010-06-17 06:00:00

MOUNTAIN VIEW, Calif., June 17 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced the recent publication of a clinical study comparing results obtained in the treatment of diabetic macular edema (DME) using an IRIDEX laser and MicroPulse(TM) treatment protocol to those obtained using the recognized standard of care Early Treatment of Diabetic Retinopathy Study (ETDRS) laser protocol. At one year, the prospective, randomized study demonstrated that a MicroPulse protocol...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'